Pharmacokinetics of topiramate during pregnancy

Epilepsy Research

Volumn 87, Issue 2-3, 2009, Pages 124-129

  Öhman, Inger ^a   Sabers, Anne ^b   de Flon, Pierre ^c   Luef, Gerhard ^d   Tomson, Torbjörn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c ÖSTERSUND HOSPITAL   (Sweden)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Epilepsy; Pharmacokinetics; Pregnancy; Therapeutic drug monitoring; Topiramate

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG MONITORING; EPILEPSY; FEMALE; FIRST TRIMESTER PREGNANCY; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENERALIZED EPILEPSY; HUMAN; MYOCLONUS EPILEPSY; PREGNANCY; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EPILEPSY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; FRUCTOSE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, THIRD;

EID: 70449642650     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.08.004     Document Type: Article

References (24)

1. Anderson G.D. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin. Drug Metab. Toxicol. 2 (2006) 947-960
2. Bialer M., Doose D.R., Murthy B., Curtin C., Wang S.S., Twyman R.E., and Schwabe S. Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet. 43 (2004) 763-780
3. Britzi M., Perucca E., Soback S., Levy R.H., Fattore C., Crema F., Gatti G., Doose D.R., Maryanoff B.E., and Bialer M. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 46 (2005) 378-384
4. Christensen J., Sabers A., and Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 67 (2006) 1497-1499
5. Davison J.M., and Hytten F.E. The effect of pregnancy on the renal handling of glucose. Br. J. Obstet. Gynaecol. 82 (1975) 374-381
6. DeGrella R.F. Fluorescence polarization: a review of laboratory applications. Am. Biotech. Lab. 6 (1988) 29-33
7. Doose D.R., and Streeter A.J. Topiramate: chemistry, biotransformation and pharmacokinetics. In: Levy R.H., Mattson R.H., and Meldrum B.S. (Eds). Antiepileptic Drugs. 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 727-734
8. Innofluor R. Topiramate Assay System Package Insert (1997), OXIS International, Inc, Portland, OR pp. 1-4
9. Garnett W.R. Clinical pharmacology of topiramate: a review. Epilepsia 41 Suppl. (2000) S61-S65
10. Mazzucchelli I., Onat F.Y., Ozkara C., et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia (2006) 504-509
11. Mimrod D., Specchio L.M., Britzi M., Perucca E., Specchio N., La Neve A., Soback S., Levy R.H., Gatti G., Doose D.R., Maryanoff B.E., and Bialer M. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia 46 (2005) 1046-1054
12. Ohman I., Beck O., Vitols S., and Tomson T. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 49 (2008) 1075-1080
13. Pennell P.B., Newport D.J., Stowe Z.N., Helmers S.L., Montgomery J.Q., and Henry T.R. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 62 (2004) 292-295
14. Pennell P.B., Peng L., Newport D.J., Ritchie J.C., Koganti A., Holley D.K., Newman M., and Stowe Z.N. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 70 (2008) 2130-2136
15. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br. J. Clin. Pharmacol. 42 (1996) 531-543
16. Perucca E., and Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin. Pharmacokinet. 31 (1996) 29-46
17. Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol. Res. 35 (1997) 241-256
18. Petrenaite V., Sabers A., and Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. 65 (2005) 185-188
19. Sachdeo R.C., Sachdeo S.K., Levy R.H., Streeter A.J., Bishop F.E., Kunze K.L., Mather G.G., Roskos L.K., Shen D.D., Thummel K.E., Trager W.F., Curtin C.R., Doose D.R., Gisclon L.G., and Bialer M. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43 (2002) 691-696
20. Tomson T., and Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin. Pharmacokinet. 46 (2007) 209-219
21. Tomson T., Palm R., Källén K., Ben-Menachem E., Söderfeldt B., Danielsson B., Johansson R., Luef G., and Ohman I. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 48 (2007) 1111-1116
22. Tran T.A., Leppik I.E., Blesi K., Sathanandan S.T., and Remmel R. Lamotrigine clearance during pregnancy. Neurology 59 (2002) 251-255
23. Westin A.A., Reimers A., Helde G., Nakken K.O., and Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 17 (2008) 192-198
24. Westin A.A., Nakken K.O., Johannessen S.I., Reimers A., Lillestølen K.M., and Brodtkorb E. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia 50 (2009) 480-485